Egis Gyogyszergyar

Egyt Gyogyszervegyeszeti Gyar

Egis Gyogyszergyar Rt.

Muanyagipari Kutato Intezet

Egis Gyogyszergvar

Egyt Gyogyszervegyeszeti Cyar

Pal Fekete

Karoly Magyar

Denes Bezzegh

Janos Egri

Ferenc Simon

Attila Mandi

Imre Klebovich

Zoltan Toth

Attila Nagy

Laszlo Puskas

Sandor Drabant

Janos Varga

Katalin Zukovics Nee Sumeg

Maria Kiraly Nee Ignacz

Gyorgy Ujfalussy

Gabor Kovacs

Gabor Gigler

Frigyes Gorgenyi

Jozsef Reiter

Laszlo Pallos

Attila Kis-Tamas

Peter Tompe

Istvan Simonyi

Margit Csorgo

Jozsef Kelemen

Ferenc Jurak

Zoltan Vig

Erzsebet Barczay

Eva Szabo

Janos Brlik

Lajos Fekete

Ilona Sztruhar

Lajos Mahr

Attila Romvary

Peter Slegel

Hedvig Szauder Nee Lauko

Maria Krisztian

Marta Szanto

Iren Barta

Katalin Zukovics Nae Someg

Judit Kulcsar

Ilona Bor Nee Baumgartner

Eva Tamas

Tibor Kovacs

Anna Mayer Nee Almasi

Erzsebet Fellner

Ilona Bor

Katalin Zukovics

Zsuzsa Szlavy, Nee Szell

Biborka Maroshelyi, Nee Kovacs

Agnes Halbauer Nee Nagy

Andrea Sandorfalvy

Magdolna Gora, Nee Hernyes

Erzsebet Fellner, Nee Kohalmi

Gabor Sipos

Zsuzsanna Jambor Nee Hoffmann

Janos Tombor

Magdolna Gora Nee Hernyes

Zsuzsanna Jambor neHoffmann

Gizella Kiss Nee Szabo

Katalin Zukovics neSte,uml/u/ Megh

Dezso Danyi

Szvetlana Zsarnoczai Nee Kurnyecova

Sarolta Benko Nee Markus

Magdolna Kenyeres Nee Feher

The invention relates to oral solid pharmaceutical composition containing as active ingredient gemfibrozil and conventional pharmaceutical auxiliary agents comprising as surfactant bis-(2-ethyl-hexyl)-sodium-sulfosuccinate in an amount of 0.05-0.5% by weight relative to gemfibrozil content of the composition. The pharmaceutical compositions according to the present invention contain a relatively small amount of a surfactant, provide uniform dissolution of the active ingredient among the different batches and the standard deviation of the dissolution rate is low.

Gemfibrozil containing pharmaceutical compositions

The invention relates to a novel diffusion-osmotic controlled drug-release pharmaceutical composition containing a one-layer tablet core including a polymeric film-coat, a therapeutically active agent and a hydrophilic polymer; if desired, a two-layer tablet core including active agent and hydrophilic polymer in the first layer thereof and a hydrophilic polymer in the second layer thereof; at least one bore on the part of film-coat in contact with the core or core layer containing the active agent; and, if desired, containing one or more bore(s) in the part thereof in contact with the second layer containing the hydrophilic polymer, which comprises an ammonium methacrylate copolymer as coating material and hydroxypropyl-methylcellulose as hydrophilic polymer. The composition according to the invention is useful for preparing controlled drug-release tablets containing as active agents e.g. .beta.-adrenergic inhibitors (e.g. propranolol) calcium-antagonists (e.g. nifedipine), angiotensin convertase enzyme (ACE) inhibitors (e.g. captopril); prazosin; or nitroglycerol, all used in heart and circulation diseases; vasodilatory active agents (e.g. pentoxyfylline), nonsteroidal antiinflammatory agents (e.g. naproxene), analgetic drugs (e.g. morphine) and drugs acting on the central nervous system (e.g. amitriptyline, buspiron). The invention furthermore relates to a process for the preparation of the above compositions.

Diffusion-osmotic controlled drug-release pharmaceutical composition and

This invention relates to a new and improved process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]-quinazolin-2[3H]-one of formula ##STR1## (anagrelide), a valuable blood platelet antiaggregative compound. According to the process of the invention the compound of formula (I) is prepared by subjecting a new 2-cyanoiminoquinazoline derivative of the general formula ##STR2## wherein R stands for cyano or a group of the formula COOR.sup.1, in the latter R.sup.1 representing lower alkyl optionally carrying a phenyl substituent, to thermal cyclization in an acidic medium. The invention also relates to new 2-cyanoiminoquinazo-lines of the general formula (III) used for the production of anagrelide and to the preparation of the said compounds. The invention provides an advantageous process for the preparation of anagrelide which is devoid of the drawbacks of the hitherto known processes and renders possible the production of the compound of the formula (I) on industrial scale, too.

Process for the preparation of

The invention relates to the preparation of microcapsules ensuring direct tablet compression of a drug and rapid release of the drug as active ingredient from the tablets, which comprises microencapsulating the crystal granules of cyclohexane-insoluble active ingredients with a particle size of at most 1000 .mu.m, preferably smaller than 60 .mu.m and particularly preferably smaller than 30 .mu.m, in cyclohexane medium with ethylcellulose taken in an amount of 1:30 to 1:5, preferably 1:20 to 1:10, in relation to the core material, if desired, in the presence of 0.001 to 1.0% by weight/volume, preferably 0.01 to 0.05% by weight/volume, of an anionic surface-active agent; or post-treating the drug granules microencapsulated with ethylcellulose by a cyclohexane-dissolved surface-active agent taken in an amount of 0.001 to 1.0% by weight/volume, preferably 0.1 to 0.5% by weight/volume, in relation to cyclohexane.

Process for preparing microcapsules providing the rapid release of a

The invention relates to synergistically active veterinary compositions useful particularly for the treatment of mastitis and metritis. The invention further relates to a process for preparing these compositions. The compositions according to the invention comprise, based on 1 part by weight of 6,9,18-tris(2-aminoethyl) -15-benzyl-21-[.sup.- 2,8-bis(2-aminoethyl)-5-(1-hydroxyethyl) -15-methyl-4,7,10-trioxo-3,6,9-triazaheptadecanamido]-3-(1-hydroxyethyl)-1 2-isobutyl-1,4,7,10,13,16,19-heptaazacyclotricosane-2, 5,8,11,14,17,20-heptaone or a pharmaceutically acceptable acid addition salt thereof, 1 to 1000 parts by weight of 1-(2-chlorophenyl)-diphenylmethyl-1H-imidazole or 1 to 400 parts by weight of 2-methyl-5,7-dichloro-8-hydroxyquinoline, respectively, optionally in admixture with carriers and/or additives commonly used in the pharmaceutical industry.

Synergistically active veterinary compositions and process for preparing

The invention relates to weight gain-increasing compositions, particularly fodder supplement, premix, drinking water supplement, bolus and/or microcapsule containing 0.001 to 90% by weight of 1-(3,5-dihydroxyphenyl)-2-(tertiary butylamino)-ethanol or a physiologically acceptable acid addition salt thereof as active ingredient in admixture with inert solid and/or liquid carrier(s).

Method for weight gain-increasing of fodder utilization of pigs, cattle

The invention relates to a synergistic veterinary composition and/or a fodder premix useful for preventing or curing bacterial, fungal and protozoic infection particularly occurring at poultry species. Furthermore the invention relates to a process for preparing same. The composition or premix contains 1 to 100 parts by mass of 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine and/or 1 to 100 parts by mass of 2,4-diamino-5-(3,4-dimethoxybenzyl)pyrimidine as well as 1 to 100 parts by mass of 2,6-dimethoxy-4-sulfanilamidopyrimidine or a pharmaceutically acceptable salt thereof and 1 to 100 parts by mass of 8-hydroxyquinoline or a pharmaceutically acceptable acid addition salt thereof optionally in admixture with carrier(s) and/or additive(s) commonly used in the pharmaceutical industry or for the preparation of premixes.

Synergistic veterinary composition and/or fodder premix and process for

The invention relates to a transdermal laminated pharmaceutical composition (plaster) having prolonged effect, wherein one or more storing layer(s) comprising the active ingredient, an ethylene/vinyl acetate copolymer regulating layer and an adhesive layer are applied onto the carrier. The pharmaceutical composition is prepared by coupling a carrier comprising the active ingredient with a regulating layer consisting of an ethylene/vinyl acetate copolymer foil having a vinal acetate content of 2-40 molar %. The foil is previously irradiated in a thickness of 100-300 .mu.m with a high-energy irradiation in a dose of 1-15 Mrad--preferably with electrone radiation--and thereafter stretched at 80.degree.-90.degree. C. to a thickness of 2-200 .mu.m. The system comprising the carrier and the regulating layer is subsequently coupled with an adhesive layer.

Transdermal laminated pharamaceutical compositions having prolonged

Stabilized insecticidal composition and process for the preparation

Process for the preparation of sustained release pharmaceutical

The invention relates to new plant growth regulating compositions, which contain as active agent 0.001 to 95% by weight of one or more compound(s) of the general formula (I), ##STR1## wherein R.sup.1 and R.sup.2 each represent hydrogen atom, a C.sub.1-5 alkyl group, a C.sub.5-7 cycloalkyl group, an aryl group, a halogen-substituted aryl group, an aralkyl group, a C.sub.2-5 alkenyl group or a C.sub.2-5 alkynyl group, or

Plant growth regulating compounds and compositions and a process for the

The invention provides a method for preparing sustained release tablets comprising a hydrophilic polymer matrix, which amounts to at least 10% by weight of the composition, consisting of a 5:1-1:5 weight to weight ratio mixture of a VP-VA copolymer and of an acrylic acid homopolymer, cross-linked with polyallyl saccharose. The method of manufacturing of sustained release tablets according to the invention can be accomplished in two ways: either by manufacturing the granulate containing the active ingredient, or by supplementing the matrix granulate containing no active ingredient with the suitable amount of the active ingredient. The latter variant involves the advantage of a possible separation of large-scale manufacturing of pharmacons and that of a generally applicable retardizing system, the composition and, consequently, the retardizing ability of which can optionally be modified in accordance with the properties of the active ingredient(s) to be formulated.

Sustained release pharmaceutical tablets and process for the preparation

Growing community of inventors

Budapest, Hungary

Pal Fekete